retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity is gaining attention in metabolic research for its activity on GIP, GLP-1, and receptors. In this carousel, we summarize recent clinical study findings related to weight management, type Retatrutide: The GLP-1/GIP/Glucagon Triple-Agonist Guide

Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials

This multi-strain probiotic is formulated with beneficial bacteria that naturally increase GLP-1, the un-hunger hormone that helps curb cravings & appetite

This is just a glimpse of the GLP-1 insights available to CivicScience clients

Wegovy.

others seek natural alternatives to the prescriptions

evidence from uncontrolled designs (case reports, case series, pharmacovigilance analyses) was initially rated very low certainty, as these designs are inherently uncontrolled and start below the lowest GRADE tier